States Cannot Avoid Regeneron Counterclaims in False Claims Act Case

In a significant legal development, federal courts have denied sovereign immunity protection to eleven states pursuing False Claims Act litigation against Regeneron Pharmaceuticals, allowing the company to proceed with its counterclaims in the ongoing dispute over eye medication pricing.

The states had sought to block Regeneron’s counterclaims by invoking sovereign immunity, a legal doctrine that typically shields government entities from being sued. However, the court determined that by initiating the False Claims Act case, the states had effectively waived this protection.

At the center of the dispute are allegations that Regeneron artificially inflated reimbursement claims for one of its ophthalmologic medications, resulting in excessive payments from state-funded healthcare programs. The drug in question is believed to be Eylea (aflibercept), Regeneron’s blockbuster treatment for wet age-related macular degeneration and other serious eye conditions that has generated billions in annual revenue since its approval in 2011.

The states argue that Regeneron’s pricing practices violated the False Claims Act, which prohibits companies from knowingly submitting false or fraudulent claims to government programs. Such violations can result in substantial financial penalties, including treble damages and additional fines per false claim.

Regeneron has contested these allegations vigorously and filed counterclaims against the states, the specifics of which remain partially sealed. Legal experts suggest these counterclaims likely challenge the states’ interpretation of pricing regulations or allege improper conduct in how the investigation was handled.

“This ruling represents an important procedural victory for pharmaceutical companies facing state-led False Claims Act cases,” said Jonathan Maxwell, healthcare litigation expert at Benson & Harriman LLP, who is not involved in the case. “It establishes that states cannot use sovereign immunity as both a sword and shield in these disputes.”

The pharmaceutical pricing landscape has become increasingly contentious in recent years, with government entities at both federal and state levels intensifying scrutiny of drug pricing practices. This case joins numerous others targeting pharmaceutical manufacturers over alleged pricing improprieties.

Industry analysts note that the financial stakes in such litigation can be enormous. False Claims Act cases frequently result in settlements reaching hundreds of millions or even billions of dollars. In 2022 alone, pharmaceutical companies paid over $2.8 billion to resolve False Claims Act allegations related to various pricing and marketing practices.

Regeneron, headquartered in Tarrytown, New York, has emerged as a pharmaceutical powerhouse over the past decade. Beyond Eylea, the company has developed several successful medications, including Dupixent for inflammatory conditions and monoclonal antibody treatments for COVID-19.

The company’s stock showed minimal movement following news of the ruling, suggesting investors had already factored litigation risks into their valuations. Pharmaceutical industry observers note that while such legal challenges create uncertainty, they rarely fundamentally alter business models in the sector.

“Investors understand that major pharmaceutical companies typically face ongoing litigation as part of doing business in a heavily regulated industry,” explained Maria Torres, pharmaceutical sector analyst at Capital Market Insights. “What matters more is the strength of the product pipeline and market exclusivity timelines.”

The case will now proceed with both the states’ claims and Regeneron’s counterclaims active, potentially extending the timeline for resolution. Legal experts anticipate intensive discovery proceedings as both sides gather evidence to support their positions.

This ruling could have broader implications for how states approach False Claims Act enforcement against pharmaceutical companies. States may need to carefully consider the potential exposure created when they waive sovereign immunity by initiating such actions.

The eleven states involved include several with large Medicaid programs, though the specific roster of states participating has not been fully disclosed in public documents. The financial impact on state healthcare budgets and the precedent for future pharmaceutical pricing enforcement actions ensure this case will remain closely watched by industry stakeholders.